Inhibition of in vitro VEGF expression and choroidal neovascularization by synthetic dendrimer peptide mediated delivery of a sense oligonucleotide

被引:72
作者
Marano, RJ
Wimmer, N
Kearns, PS
Thomas, BG
Toth, I
Brankov, M
Rakoczy, PE
机构
[1] Univ Western Australia, Lions Eye Inst, Dept Mol Ophthalmol, Ctr Ophthalmol & Visual Sci, Perth, WA 6009, Australia
[2] Univ Queensland, Sch Pharm, St Lucia, Qld 4072, Australia
基金
英国惠康基金; 英国医学研究理事会;
关键词
VEGF; dendrimer; oligonucleotide; lipidic polyamide; lipoamino acids; cationic lipids; choroid; laser photocoagulation; transfection;
D O I
10.1016/j.exer.2004.06.023
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Ocular neovascularisation is the leading cause of blindness in developed countries and the most potent angiogenic factor associated with neovascularisation is vascular endothelial growth factor (VEGF). We have previously described a sense oligonucleotide (ODN-1) that possesses anti-human and rat VEGF activity. This paper describes the synthesis of lipid-lysine dendrimers and their subsequent ability to delivery ODN-1 to its target and mediate a reduction in VEGF concentration both in vitro and in vivo. Positively charged dendrimers were used to deliver ODN-1 into the nucleus of cultured D407 cells. The effects on VEGF mRNA transcription and protein expression were analysed using RT-PCR and ELISA, respectively. The most effective dendrimers in vitro were further investigated in vivo using an animal model of choroidal neovascularisation (CNV). All dendrimer/ODN-1 complexes mediated in a significant reduction in VEGF expression during an initial 24 hr period (40-60%). Several complexes maintained this level of VEGF reduction during a subsequent, second 24 hr period, which indicated protection of ODN-1 from the effects of endogenous nucleases. In addition, the transfection efficiency of dendrimers that possessed 8 positive charges (chi = 81(.)51%) was significantly better (P = 0(.)0036) than those that possessed 4 positive charges (chi = 56(.)8%). RT-PCR revealed a correlation between levels of VEGF protein mRNA. These results indicated that the most effective structural combination was three branched chains of intermediate length with 8 positive charges such as that found for dendrimer 4. Dendrimer 4 and 7/ODN-1 complexes were subsequently chosen for in vivo analysis. Fluorescein angiography demonstrated that both dendrimers significantly (P < 0(.)0001) reduced the severity of laser mediated CNV for up to two months post-injection. This study demonstrated that lipophilic, charged dendrimer mediated delivery of ODN-1 resulted in the down-regulation of in vitro VEGF expression. In addition, in vivo delivery of ODN-1 by two of the dendrimers resulted in significant inhibition of CNV in an inducible rat model. Time course studies showed that the dendrimer/ODN-1 complexes remained active for up to two months indicating the dendrimer compounds provided protection against the effects of nucleases. (C) 2004 Elsevier Ltd. All rights reserved.
引用
收藏
页码:525 / 535
页数:11
相关论文
共 32 条
[1]   Specific inhibition of influenza virus RNA polymerase and nucleoprotein gene expression by liposomally encapsulated antisense phosphorothioate oligonucleotides in MDCK cells [J].
Abe, T ;
Suzuki, S ;
Hatta, T ;
Takai, K ;
Yokota, T ;
Takaku, H .
ANTIVIRAL CHEMISTRY & CHEMOTHERAPY, 1998, 9 (03) :253-262
[2]   INCREASED VASCULAR ENDOTHELIAL GROWTH-FACTOR LEVELS IN THE VITREOUS OF EYES WITH PROLIFERATIVE DIABETIC-RETINOPATHY [J].
ADAMIS, AP ;
MILLER, JW ;
BERNAL, MT ;
DAMICO, DJ ;
FOLKMAN, J ;
YEO, TK ;
YEO, KT .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 1994, 118 (04) :445-450
[3]   SUPPRESSION OF RETINAL NEOVASCULARIZATION IN-VIVO BY INHIBITION OF VASCULAR ENDOTHELIAL GROWTH-FACTOR (VEGF) USING SOLUBLE VEGF-RECEPTOR CHIMERIC PROTEINS [J].
AIELLO, LP ;
PIERCE, EA ;
FOLEY, ED ;
TAKAGI, H ;
CHEN, H ;
RIDDLE, L ;
FERRARA, N ;
KING, GL ;
SMITH, LEH .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (23) :10457-10461
[4]   The delivery of antisense therapeutics [J].
Akhtar, S ;
Hughes, MD ;
Khan, A ;
Bibby, M ;
Hussain, M ;
Nawaz, Q ;
Double, J ;
Sayyed, P .
ADVANCED DRUG DELIVERY REVIEWS, 2000, 44 (01) :3-21
[5]  
Alahari SK, 1996, MOL PHARMACOL, V50, P808
[6]   Inhibition of retinal neovascularisation by gene transfer of soluble VEGF receptor sFlt-1 [J].
Bainbridge, JWB ;
Mistry, A ;
De Alwis, M ;
Paleolog, E ;
Baker, A ;
Thrasher, AJ ;
Ali, RR .
GENE THERAPY, 2002, 9 (05) :320-326
[7]   DNA condensation [J].
Bloomfield, VA .
CURRENT OPINION IN STRUCTURAL BIOLOGY, 1996, 6 (03) :334-341
[8]   OLIGONUCLEOTIDES AS THERAPEUTIC AGENTS [J].
COHEN, JS .
PHARMACOLOGY & THERAPEUTICS, 1991, 52 (02) :211-225
[9]   PROGRESS TOWARD OLIGONUCLEOTIDE THERAPEUTICS - PHARMACODYNAMIC PROPERTIES [J].
CROOKE, ST .
FASEB JOURNAL, 1993, 7 (06) :533-539
[10]   INTRACELLULAR DELIVERY OF NUCLEIC-ACIDS AND TRANSCRIPTION FACTORS BY CATIONIC LIPOSOMES [J].
DUZGUNES, N ;
FELGNER, PL .
METHODS IN ENZYMOLOGY, 1993, 221 :303-306